As cancer therapies continue to evolve, antibody-drug conjugates (ADCs) are emerging as a new generation of targeted anti-cancer drugs. By combining monoclonal antibodies, linkers, and potent cytotoxic small molecules, ADCs deliver drugs directly into cancer cells with high precision. This article introduces the structure and mechanism of ADCs and explores how they achieve selective cancer … What Are ADCs? Understanding Their Structure and Cancer-Killing Mechanism Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.